InsiderTrades

Form 4 for JANX Janux Therapeutics, Inc.

Accepted 2025-12-03 00:00:00 ET · period of report 2025-12-01 · accession 0001864159-25-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-12-03 2025-12-01 JANX Meyer Andrew Hollman Chief Business Off S - Sale+OE $32.98 -3,333 85.6K -4% -$109.9K
D 2025-12-03 2025-12-01 JANX Meyer Andrew Hollman Chief Business Off M - OptEx $10.59 +3,333 88.3K +4% +$35.3K
D 2025-12-03 2025-12-01 JANX Meyer Andrew Hollman Chief Business Off M - OptEx $0.00 -3,333 114.8K -3% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-01 S D 633 $33.52 84,974 D — — (F3) The weighted average sale price for the transaction reported was $33.5247 and the range of prices were between $33.28 and $33.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
2 Common Common Stock 2025-12-01 S D 2,700 $32.85 85,607 D — — (F2) The weighted average sale price for the transaction reported was $32.8548 and the range of prices were between $32.27 and $33.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3 Common Common Stock 2025-12-01 M A 3,333 $10.59 88,307 D — —
4 Derivative Stock Option (right to buy) 2025-12-01 M D 3,333 $0.00 114,768 D $10.59 · — to 2031-05-13 3,333 Common Stock (F4) Immediately exercisable.